As described earlier, HGBL with gene rearrangements affecting MYC, BCL2 and/or BCL6, and DEL are linked to inferior treatment response [19,20], although DEL has a better prognosis compared to DHL or THL DLBCL [19,56,57,58]. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.